These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C. Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395 [Abstract] [Full Text] [Related]
15. Effects of low dose methotrexate therapy on the concentration and the glycosylation of alpha 1-acid glycoprotein in the serum of patients with rheumatoid arthritis: a longitudinal study. De Graaf TW, Van Ommen EC, Van der Stelt ME, Kerstens PJ, Boerbooms AM, Van Dijk W. J Rheumatol; 1994 Dec; 21(12):2209-16. PubMed ID: 7699621 [Abstract] [Full Text] [Related]
16. Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Wijngaarden S, van Roon JA, van de Winkel JG, Bijlsma JW, Lafeber FP. Rheumatology (Oxford); 2005 Jun; 44(6):729-34. PubMed ID: 15757966 [Abstract] [Full Text] [Related]
17. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P. Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189 [Abstract] [Full Text] [Related]
18. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344 [Abstract] [Full Text] [Related]
19. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M. Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169 [Abstract] [Full Text] [Related]
20. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Charni N, Juillet F, Garnero P. Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703 [Abstract] [Full Text] [Related] Page: [Next] [New Search]